1. Home
  2. DRDB vs TNYA Comparison

DRDB vs TNYA Comparison

Compare DRDB & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DRDB
  • TNYA
  • Stock Information
  • Founded
  • DRDB 2024
  • TNYA 2016
  • Country
  • DRDB United States
  • TNYA United States
  • Employees
  • DRDB N/A
  • TNYA N/A
  • Industry
  • DRDB
  • TNYA Medicinal Chemicals and Botanical Products
  • Sector
  • DRDB
  • TNYA Health Care
  • Exchange
  • DRDB Nasdaq
  • TNYA Nasdaq
  • Market Cap
  • DRDB 320.0M
  • TNYA 326.0M
  • IPO Year
  • DRDB 2024
  • TNYA 2021
  • Fundamental
  • Price
  • DRDB $10.45
  • TNYA $1.25
  • Analyst Decision
  • DRDB
  • TNYA Strong Buy
  • Analyst Count
  • DRDB 0
  • TNYA 5
  • Target Price
  • DRDB N/A
  • TNYA $8.60
  • AVG Volume (30 Days)
  • DRDB 34.8K
  • TNYA 3.9M
  • Earning Date
  • DRDB 01-01-0001
  • TNYA 11-10-2025
  • Dividend Yield
  • DRDB N/A
  • TNYA N/A
  • EPS Growth
  • DRDB N/A
  • TNYA N/A
  • EPS
  • DRDB N/A
  • TNYA N/A
  • Revenue
  • DRDB N/A
  • TNYA N/A
  • Revenue This Year
  • DRDB N/A
  • TNYA N/A
  • Revenue Next Year
  • DRDB N/A
  • TNYA N/A
  • P/E Ratio
  • DRDB $597.54
  • TNYA N/A
  • Revenue Growth
  • DRDB N/A
  • TNYA N/A
  • 52 Week Low
  • DRDB $9.87
  • TNYA $0.36
  • 52 Week High
  • DRDB $10.47
  • TNYA $4.01
  • Technical
  • Relative Strength Index (RSI)
  • DRDB 58.94
  • TNYA 39.92
  • Support Level
  • DRDB $10.42
  • TNYA $1.20
  • Resistance Level
  • DRDB $10.47
  • TNYA $1.56
  • Average True Range (ATR)
  • DRDB 0.02
  • TNYA 0.15
  • MACD
  • DRDB -0.00
  • TNYA -0.02
  • Stochastic Oscillator
  • DRDB 71.43
  • TNYA 19.42

About DRDB Roman DBDR Acquisition Corp. II Ordinary shares

Roman DBDR Acquisition Corp II is a blank check company.

About TNYA Tenaya Therapeutics Inc.

Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.

Share on Social Networks: